Cargando…
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial
BACKGROUND AND AIMS: Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied. METHODS A...
Autores principales: | Andersson, Charlotte, Weeke, Peter, Brendorp, Bente, Køber, Lars, Fosbøl, Emil L, Sharma, Arya M, Finer, Nick, Caterson, Ian D, Rode, Richard A, James, Philip T, Torp-Pedersen, Christian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768730/ https://www.ncbi.nlm.nih.gov/pubmed/19828038 http://dx.doi.org/10.1186/1743-7075-6-42 |
Ejemplares similares
-
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period
por: Weeke, Peter, et al.
Publicado: (2010) -
Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A substudy of the SCOUT trial
por: Ghotbi, Adam Ali, et al.
Publicado: (2013) -
Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals
por: Skak-Nielsen, Helle, et al.
Publicado: (2013) -
Sibutramine on Cardiovascular Outcome
por: Scheen, André J.
Publicado: (2011) -
Phentermine, Sibutramine and Affective Disorders
por: An, Hoyoung, et al.
Publicado: (2013)